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Polycomb Repressive Complex 2 (PRC2) modifies chromatin to silence many embryonic patterning genes,
restricting their expression to the appropriate cell populations. Two reports in Cell by Peng et al. (2009)
and Shen et al. (2009) identify Jarid2/Jumonji, a new component of PRC2, which inhibits PRC2 enzymatic
activity to fine-tune silencing.Covalent modification of histones is
central in regulation of gene expression
in metazoans. The Polycomb Repressive
Complex 2 (PRC2), which trimethylates
histone H3 on lysine 27 (H3K27me3), is
necessary for the correct spatio-temporal
maintenance of silencing at genes in-
volved in developmental patterning, mor-
phogenesis, and organogenesis. The core
subunits of mammalian PRC2—enhancer
of zeste (Ezh2), the lysine methyltransfer-
ase (KMT), and embryonic ectoderm
development (Eed) and suppressor of
zeste 12 (Suz12), associated proteins that
are essential for its enzymatic activity—
exist in multiple complexes (Simon and
Kingston, 2009). However, the composi-
tion and function of the different PRC2
complexes have yet to be fully elucidated.
In a recent issue of Cell, papers from the
Wysocka and Orkin labs provide a
surprising new insight into one PRC2
complex (Peng et al., 2009; Shen et al.,
2009). Both groups show that a fraction
of PRC2 associates with Jarid2/Jumonji
(Jarid2), which inhibits PRC2’s KMT and
silencing activities. They suggest that
Jarid2 fine-tunes the degree of Poly-
comb-mediated silencing and thereby
can influence cell-fate decisions.
Peng et al. and Shen et al. affinity-puri-
fied PRC2 from mouse embryonic stem
cells (ESCs) by employing tagged core
subunits and found that PRC2 associates
with Jarid2 (Peng et al., 2009; Shen et al.,
2009). In addition, genome-wide localiza-
tion analyses showed that Jarid2 is found
at the vast majority of sites bound by
PRC2 in ESCs. Together, these data sug-
gest that a significant fraction of PRC2 is
associated with Jarid2 in ESCs.
Jarid2 is the founding member of the
Jumonji C (Jmjc) domain family. Jmjc
domains are characteristic of proteins
that remove methyl groups, the lysinedemethylases (KDMs) (Lan et al., 2008).
Jarid2 is unusual among Jmjc proteins in
that it lacks crucial residues for cofactor
binding and is a catalytically inactive
KDM (Lan et al., 2008; Shen et al., 2009).
The association of KMT and KDM com-
plexes is thought to be important in
maintaining chromatin in an on or off
state. For example, KMTs that modify
histone H3 on lysine 4 (H3K4me), a mark
associated with gene activation, asso-
ciate with the H3K27 KDM, thereby
coupling the addition of an activating
mark with the removal of a silencing
mark (Swigut and Wysocka, 2007). Simi-
larly, Jarid1a, a H3K4 KDM, is reported
to associate with PRC2 (Pasini et al.,
2008). However, Jarid2 is substantially
more abundant than Jarid1a in ESCs
and PRC2-Jarid2 is the predominant
KMT-Jmjc complex in ESCs. It may be
that the association of PRC2 with Jarid2
is one of the reasons that many of the
genes silenced by PRC2 in ESCs contain
both H3K27me3 and H3K4me3, a combi-
nation of silencing and activemarks that is
thought to be central in keeping these
genes poised for expression in the future
(Bernstein et al., 2006).
Peng et al. and Shen et al. provide
several lines of evidence to indicate that
Jarid2 functions as more than just a
catalytically inactive KDM. First, Jarid2
is necessary for normal levels of PRC2
association with its target genes. This
requirement is mutual, given that Jarid2
binding was also decreased in PRC2
mutant cells. Second, Jarid2 inhibits
PRC2 H3K27 KMT activity in vitro. Third,
Jarid2 mutant ESCs exhibit increased
H3K27me3 levelsatPRC2 targets, despite
decreased occupancy of PRC2. Further-
more, whereas PRC2-bound genes are
upregulated in PRC2 mutant ESCs, these
genes are downregulated in Jarid2mutantCell Stem CeESCs. Finally, whereas gene expression
changes in differentiating PRC2 mutant
ESCs are indicative of accelerated differ-
entiation, differentiating Jarid2 mutant
ESCs exhibit gene expression changes
consistent with delayed differentiation.
A similar trend was observed in vivo,
when the Xenopus Jarid2 homolog was
depletedduring frog early embryogenesis.
Thus, Jarid2 promotes association of
PRC2 with its target genes while simulta-
neously inhibiting PRC2enzymatic activity
and attenuating silencing, which in turn
promotes expression of differentiation-
specific genes. The precise mechanism
by which Jarid2 inhibits PRC2 activity is
not known. However, Jarid2 directly inter-
acts with Suz12 in vitro (Peng et al., 2009),
suggesting that it may interfere with the
function of this essential PRC2 subunit.
The PRC2-Jarid2 complex is not likely
to be the only flavor of PRC2 complex.
Jarid2 and PRC2 cofractionate in high-
molecular-weight complexes on glycerol
gradients; however, there were lower-
molecular-weight PRC2 complexes that
lacked Jarid2 (Peng et al., 2009). Shen
et al. also show that PRC2 interacts with
metal response element-binding tran-
scription factor (Mtf2) (Shen et al., 2009),
one of three mammalian homologs of
Drosophila Polycomblike (Pcl), which
binds fly PRC2 and stimulates its activity
(Nekrasov et al., 2007). PRC2-Jarid2
and PRC2-Mtf2 are likely to be distinct
complexes because Jarid2 and Mtf2
do not copurify. Why are there so many
different PRC2-containing complexes?
One possibility is that the degree of
silencing must be exquisitely controlled
to achieve developmentally correct transi-
tions in gene expression patterns as cells
differentiate. If PRC2 activity is very high,
as is the case in Jarid2 mutant ESCs,
then the strength of any developmentalll 6, January 8, 2010 ª2010 Elsevier Inc. 3
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silenced genes may not be sufficient to
reliably induce expression of their targets.
When PRC2 activity is low, as in Eed or
Suz12mutants, target genes are no longer
reliably silenced, and such a result can
lead to incorrect execution of develop-
mental programs (Chamberlain et al.,
2008; Pasini et al., 2007). Indeed, Eed
mutant ESCs are prone to differentiation
in culture, suggesting that PRC2 is neces-
sary for ESCs to robustly carry out the self-
renewal program. Thus, one possibility is
that the ratio of different PRC2 complexes
occupying each target gene may be
important in determining whether a sig-
naling pathway will trigger maintenance
of or release from silencing, thus allowing
cells to silence or upregulate a subset of
PRC2 targets in response to particular
developmental cues.
The near-perfect overlap between
Jarid2 and PRC2 in ESCs argues that it
is not simply the presence or absence of
Jarid2 that regulates PRC2 target gene
activity. However, in addition to Jarid24 Cell Stem Cell 6, January 8, 2010 ª2010 Eland Mtf2 and other Pcl homologs, there
are several other sources of variability
between PRC2 complexes (Simon and
Kingston, 2009). Specifically, there are
two related genes encoding H3K27
KMTs, Ezh2 and Ezh1, both of which
associate with Eed and Suz12 and there
are four isoforms of Eed that differ in
their N-termini because of alternative
translation-start-site usage. Thus, there
is potential for considerable combinatorial
complexity of PRC2 complexes. Once the
composition and activities of different
PRC2 complexes is determined, and the
factors that direct these different com-
plexes to their target genes are identified,
it may be possible to fully understand how
PRC2 is utilized to control so many genes
in such a wide variety of developmental
contexts.
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A recent study in Nature Cell Biology, Wellner et al. (2009) identifies ZEB1, a known promoter of tumor inva-
sion, as a negative regulator of miRNA clusters that target stem cell factors. These findings provide new
insight into the network of transcription factors and miRNAs that regulate cancer stem cells.Treatment of human cancers is compli-
cated because the majority of cancers
become metastatic and/or develop resis-
tance to therapy. Two concepts that may
explain tumor progression and acquisition
of a therapy-resistant phenotype have
received wide attention. In the first con-
cept, tumor cells gain an invasive pheno-
type by a process that resembles the
epithelial tomesenchymal transition (EMT)
found during embryonic development and
wound healing. During EMT, cells change
morphology, lose polarity, and becomemobile. The second concept is based on
the recognition that many human cancers
containa rarepopulationofcells that exhibit
stem cell properties and drive neoplastic
growth. Recent data have connected the
two concepts in breast cancer by demon-
strating that induction of EMT in both
mammaryepithelialcellsaswell as inbreast
cancer cells causes upregulation of stem
cell markers (Mani et al., 2008). Conversely,
EMTmarkers were found to be enriched in
stem cells isolated from either mammary
glands or mammary carcinomas.miRNAs have emerged as powerful
regulators of differentiation, and a number
of miRNAs have been shown to be either
highly expressed or excluded from stem
cells. miRNAs that are highly expressed
in stem cells include the miR-302371
cluster; expression of miR-302 alone in
human skin cancer cells induced a pheno-
type that included properties of pluripo-
tent embryonic stem cells (Lin et al.,
2008). Examples of miRNAs excluded
from embryonic stem cells are let-7 (Yu
et al., 2007) and miR-145, which targets
